Alpha 2.0
Login Register
» Articles » PMID: 1316311

Topoisomerase-targeting Antitumor Drugs: Mechanisms of Cytotoxicity and Resistance

Overview
Journal Important Adv Oncol
Specialty Oncology
Date 1992 Jan 1
PMID 1316311
Citations 12
Authors
L F Liu
P DArpa
Affiliations
Soon will be listed here.
Citing Articles

Determining success rates of the current pharmacokinetically guided dosing approach of topotecan in pediatric oncology patients.

Mitchell A, Vasilyeva A, Gajjar A, Santana V, Stewart C Pediatr Blood Cancer. 2018; 66(4):e27578.

PMID: 30548417 PMC: 6386591. DOI: 10.1002/pbc.27578.

Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons.

Gibson E, Blower T, Cacho M, Bax B, Berger J, Osheroff N ACS Infect Dis. 2018; 4(8):1211-1222.

PMID: 29746087 PMC: 6309371. DOI: 10.1021/acsinfecdis.8b00035.

Activities of gyrase and topoisomerase IV on positively supercoiled DNA.

Ashley R, Dittmore A, McPherson S, Turnbough Jr C, Neuman K, Osheroff N Nucleic Acids Res. 2017; 45(16):9611-9624.

PMID: 28934496 PMC: 5766186. DOI: 10.1093/nar/gkx649.

Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 inhibition.

Palle K, Vaziri C Cell Cycle. 2011; 10(10):1625-38.

PMID: 21478670 PMC: 3127162. DOI: 10.4161/cc.10.10.15617.

DNA topoisomerase II, genotoxicity, and cancer.

McClendon A, Osheroff N Mutat Res. 2007; 623(1-2):83-97.

PMID: 17681352 PMC: 2679583. DOI: 10.1016/j.mrfmmm.2007.06.009.